VIP and myeloid sarcoma: This approach may help with the identification of novel protective mechanisms of PACAP and VIP to reduce oligodendrocyte loss and perhaps promote myelin repair in chronic demyelinating pathologies such as MS, whilst also offering new opportunities for therapeutic intervention.